A 64-year-old man with chronic coronary disease and angina despite optimal antianginal therapy asks about antithrombotic therapy. He has no atrial fibrillation, prior stroke, or high bleeding risk. Which approach is endorsed for stable CCD to reduce major adverse cardiovascular events?